MBP and neoplasm: The ability of the vaccine to reduce Th17 cell activity was lower in mice immunized eight times than in those immunized five times, suggesting that the recombinant MUC1-MBP vaccine may control tumor growth by reducing Th17 and that excessive immunization cycles attenuated the recombinant MUC1-MBP vaccine-induced downregulation of Th17 cells.